Sign up to save your podcasts
Or
Share FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening
JCO PO author Dr. Wainberg at UCLA shares insights into the JCO PO article, "Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial." Host Dr. Rafeh Naqash and Dr. Wainberg discuss how FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expression.
TRANSCRIPT TO COME
View all episodes
By American Society of Clinical Oncology (ASCO)
5
33 ratings
JCO PO author Dr. Wainberg at UCLA shares insights into the JCO PO article, "Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial." Host Dr. Rafeh Naqash and Dr. Wainberg discuss how FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expression.
TRANSCRIPT TO COME
More shows like JCO Precision Oncology Conversations
View all
JAMA Clinical Reviews
503 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
ASCO Daily News
58 Listeners
Pod Save America
87,787 Listeners
The Daily
113,219 Listeners
Core IM | Internal Medicine Podcast
1,148 Listeners
OncLive® On Air
22 Listeners
VJOncology Podcast
2 Listeners
The Clinical Problem Solvers
516 Listeners
The Uromigos
61 Listeners
Oncology On The Go
4 Listeners
The Lancet Oncology in conversation with
1 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
46 Listeners
Oncology for the Inquisitive Mind
4 Listeners
Oncology Decoded
23 Listeners